Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 19Magnetic Resonance Spectroscopy 15Radiotherapy 14Specimen Handling 13Radiation 9Biopsy 5pembrolizumab 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Bevacizumab 4vorasidenib 3trametinib 3Surgical Procedures, Operative 3Spinal Puncture 3tovorafenib 2dabrafenib 2Restraint, Physical 2Leukapheresis 2Ipilimumab 2Genetic Therapy 2Fluorodeoxyglucose F18 2Eflornithine 2Craniotomy 2Carboplatin 214-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene 2vocimagene amiretrorepvec 1veliparib 1trastuzumab deruxtecan 1tozuleristide 1tocilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × vocimagene amiretrorepvec × 1 year × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡